1 <!DOCTYPE html> <html lang="en"> <head> <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" /> <meta charset="utf-8" />
1<script type="text/html" id="sf-tracking-consent-manager"> 2 <style> 3 /*Consent Form*/ 4 #tracking-consent-dialog { 5 padding: 15px; 6 position: fixed; 7 bottom: 0; 8 right: 5px; 9 width: 337px; 10 border: 3px solid #1e82e0; 11 border-radius: 5px 5px 0px 0px; 12 background: rgba(255, 255, 255, .95); 13 font-size: 16px; 14 z-index: 999; 15 } 16 #tracking-consent-dialog-accept { 17 background-color: #1e82e0; 18 color: #fff; 19 font-size: 16px; 20 font-weight: 500; 21 float: right; 22 } 23 .consent-close { 24 font-weight: bold; 25 float: right; 26 padding: 2px 7px; 27 right: 6px; 28 top: 3px; 29 cursor: pointer; 30 font-size: 11px; 31 position: absolute; 32 background-color: #1e82e0; 33 color: #fff; 34 z-index: 999; 35 border-radius: 50%; 36 } 37 @media (max-width: 767px) { 38 #tracking-consent-dialog { 39 width: 100%; 40 font-size: 14px; 41 } 42 43 } 44 45 </style> 46 47 48 49 <div id="tracking-consent-dialog"> 50 <div class="consent-close" onclick="TrackingConsentManager.updateUserConsent(true)">X</div> 51 <strong>Cookie Policy</strong> 52 <p>CII uses cookies to improve your website & conference experiences, including enhancing website navigation, personalized features & promotions, evaluating our services, and customizing content and ads based on your preferences as you browse or engage with us. By clicking "Continue" or continuing to use our site, you are agreeing to our and our partners use of cookies. See our <a href="https://www.cambridgeinnovationinstitute.com/Privacy-Policy/">Privacy Policy</a> for more information.</p> 53 <button type="button" onclick="TrackingConsentManager.updateUserConsent(true)" id="tracking-consent-dialog-accept" class="btn btn-default">Continue</button> 54 55 </div> 56</script>
56<script type="text/javascript" src="/WebResource.axd?d=DzHrpQl5URXarFHAtrmzFrNeeCwCLwHK2gvGZ95fW9WnidZLXrfDlGTuxUr3l463ttkzDVh9D8Bug9pu7NHdr_V4jKJPpR5aBflu4f8Ts5edKoXW2sH8LcSZSfqlYNJ5LpoUn5WBE_fdKcz0yNVMxY3w_4XLcip6ESbZeM3DDdUqeeNFFCEiKQKGKqR186oo0&t=638923853240000000"> 57 58</script>
58
58<script src="/ScriptResource.axd?d=6DQe8ARl7A9TiuWej5ttCjzXg7ZeGsjA61S79L0nlUTqV51Ub8wV91R_y-eCrcU7F8uEosuVthekRg-VgkVz511bOJXhhk6_-7G6xkSM3SYqLbOTg8WZ7Ipdj19ND8peMRGs-9lAeD63xpdFq0slV4gFTlsCCrVzW5AIuZdtd333QEz-rgpFJL66D9NG_fVR0&t=112ac451" type="text/javascript"></script>
58<script src="/ScriptResource.axd?d=74FHISOx3fOPKwLxL0RMYt4rXRL5d8HQcQcCifqOjyl1nBUNlI0PzkGZIEinPSExUNpNkcQhq5OsVQmd7sTcZCnUNh6BwoJFHgHEinTjxevEYpnXObtBbio1yjU4YqbTFRIhxtyFHFzSujDAOJUSMsb9x-xdttyvPJp0DTv7WQN42I71qDvgSEjK6TT2wtzQ0&t=112ac451" type="text/javascript"></script>
58<link href="/ResourcePackages/Bootstrap/assets/dist/css/main.min.css" rel="stylesheet" type="text/css" /><link href="/css/global.css" rel="stylesheet" type="text/css" /><link href="/css/editor.css" rel="stylesheet" type="text/css" /> <link href="//fonts.googleapis.com/css?family=Roboto:500,400,700" rel="stylesheet" type="text/css"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no" /> <meta property="og:title" content="Speakers - Clinical Trial Innovation Summit 2018" /><meta property="og:url" content="https://www.clinicaltrialsummit.com/speakers" /><meta property="og:type" content="website" /><meta property="og:site_name" content="Clinical Trials Summit" />
58<script type="text/javascript">
vendor: 325 bytes, lines 58-59
58 59(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','
59GTM-KC9X826
vendor: 7 bytes, lines 59-60
59'); 60
61</script>
61<link href="/css/20/ctl/style-ctl.css" media="all" rel="stylesheet" type="text/css" />
61<script type="text/javascript"> 62 adroll_adv_id = "MR7BZ6E5YBH3DBLFTS57OI"; 63 adroll_pix_id = "ICGW6X7DUNBQVDG4BOYYEB"; 64 /* OPTIONAL: provide email to improve user identification */ 65 /* adroll_email = "[email protected]"; */ 66 (function () { 67 var _onload = function(){ 68 if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return} 69 if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return} 70 var scr = document.createElement("script"); 71 var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com"); 72 scr.setAttribute('async', 'true'); 73 scr.type = "text/javascript"; 74 scr.src = host + "/j/roundtrip.js"; 75 ((document.getElementsByTagName('head') || [null])[0] || 76 document.getElementsByTagName('script')[0].parentNode).appendChild(scr); 77 }; 78 if (window.addEventListener) {window.addEventListener('load', _onload, false);} 79 else {window.attachEvent('onload', _onload)} 80 }()); 81</script>
81<script type="text/javascript"> 82var link = document.createElement('link'); 83link.id = 'dynamic-favicon'; 84link.rel = 'shortcut icon'; 85link.href = '/images/librariesprovider49/template-images/19/favicon.png'; 86document.head.appendChild(link); 87</script>
87<meta name="Generator" content="Sitefinity 15.3.8525.0 DX" /><link rel="canonical" href="https://www.clinicaltrialsummit.com/speakers" />
87<script type="application/json" id="sf-insight-metadata"> 88 {"contentMetadata":"{\"Id\":\"484edf1e-fd00-4e2e-b491-15fcb4b779a8\",\"ContentType\":\"Page\",\"Title\":\"Speakers\",\"CanonicalTitle\":\"Speakers\",\"CanonicalUrl\":\"https://www.clinicaltrialsummit.com/speakers\",\"DefaultLanguage\":\"en\",\"CreatedOn\":\"2018-09-12T19:39:24Z\",\"ModifiedOn\":\"2020-06-03T19:13:41Z\",\"SiteId\":\"8b03cbc8-6a7c-43a8-b174-7fe37dcaf5f9\",\"SiteName\":\"Clinical Trials Summit\",\"PageId\":\"484edf1e-fd00-4e2e-b491-15fcb4b779a8\"}","videosMetadata":"[]"} 89</script>
89<script type="application/json" id="sf-insight-settings"> 90 {"apiServerUrl":"https://api.insight.sitefinity.com/","apiKey":"62dc77b5-9fbc-74c6-8f79-d05463f0565e","applicationName":"CII_DEC","trackingCookieDomain":"","keepDecTrackingCookieOnTrackingConsentRejection":false,"slidingExpirationForTrackingCookie":false,"maxAgeForTrackingCookieInDays":365,"trackYouTubeVideos":true,"crossDomainTrackingEntries":["clinicaltrials.cambridgeinnovationinstitute.com","www.digitalmedicinecongress.com","medtechmvp.com","www.dxinnovationsummit.com","www.bio-itworldexpo.com","www.foodmedicinepolicysummit.com","www.optcongress.com","www.neurotechpartnering.com","www.manufacturingx0.com","www.decodeaipharma.com","www.hersusa.com","www.pawsforacuresymposium.com","biologicaltherapeutics.cambridgeinnovationinstitute.com","www.aiinnovationcircle.com","www.diagnosticsworldnews.com","www.bioprocessingeurope.com","bioprocessing.cambridgeinnovationinstitute.com","www.immuno-oncologysummit.com","www.innov8health.org","www.degradersandglues.com","www.liquidbiopsysummit.com","www.innateimmunotherapysummit.com","www.alliancemanagementcongress.com","www.foodmedicinesummit.com","drugdevelopment.cambridgeinnovationinstitute.com","www.sensorsglobalsummit.com","www.clinicalresearchnewsonline.com","www.scopesummit.com","www.cambridgevip.com","www.scopesummiteurope.com","www.bio-itworld.com","healthcare.cambridgeinnovationinstitute.com","chemistry.cambridgeinnovationinstitute.com","www.altamet.com","www.pegsummit.com","www.pegsummiteurope.com","www.antibacterialdrugdevelopmentsummit.com","www.iotbuildusa.com","www.aiworldgov.com","www.covid-19webinars.com","www.executivedecisionmaking.com","www.biotherapeuticsanalyticalsummit.com","www.nextgen.com","www.dtxglobalsummit.com","www.nextgenerationdx.com","www.merckbostonsymposium.com","genomics.cambridgeinnovationinstitute.com","www.scopeleadershipforum.com","dhis.net","www.barnettinternational.com","www.biologicsinsights.com","www.clinicaltrialsummit.com","www.worldpreclinicaleurope.com","www.prenatal-dx.com","www.immunogenicitysummit.com","www.biodetectiontechnologies.com","www.drugdiscoverychemistry.com","biopharmastrategy.cambridgeinnovationinstitute.com","www.internationalbatteryseminar.com","www.conqueringobesitysummit.com","www.bispecificantibodycongress.com","www.biodefenseworldsummit.com","biomarkers.cambridgeinnovationinstitute.com","www.dentalvipsummit.com","evaluatingbiopharma.com","www.cinnovationinst.com","www.amrcongress.com","www.chi-peptalk.com","www.bio-itworldexpowest.com","www.biologicsummit.com","attendais.com","www.triconference.com","www.supplychainx0.com","www.oncologyvipsummit.com","www.ciiresource.com","drugtargets.cambridgeinnovationinstitute.com","www.immuno-oncologyeurope.com","www.biomarkerworldcongress.com","aiworld.com","www.discoveryontarget.com","www.altamet.com.au","www.biobankingcongress.com","www.bio-itworldeurope.com","www.protacsummit.com","www.platformvipsummit.com","www.worldpreclinicalcongress.com","druganddevice.cambridgeinnovationinstitute.com","www.healthtech.com","www.advancedautobat.com","techtools.cambridgeinnovationinstitute.com","www.bioprocessingsummit.com","www.pegsymposium.com","www.pharmaweek.com","www.cambridgeenertech.com","www.cambridgeinnovationinstitute.com","www.goodclinicalpractice.com","it.cambridgeinnovationinstitute.com","www.moleculardxeurope.com","www.ep3msummit.com","www.futureofmentalhealthcare.com","therapeutics.cambridgeinnovationinstitute.com"],"strategy":"Persist|False","docsHrefTestExpressions":[".*\\/docs\\/.+\\.{1}.+((\\?|\\\u0026)sfvrsn=.+){1}$",".+((\\?|\\\u0026)sf_dm_key=.+){1}$"],"sessionLengthInMinutes":30,"trackVimeoVideos":true,"useSecureCookies":true} 91</script>
91<script type="text/javascript" src="/WebResource.axd?d=HtQyXelCu6mzSPcVcvK_BrDGcMZ2eaAwTGCTL_5l9xvo0iV9h2YYkvXanQ1uf0LidxbxWd8AzxNrppPmU7C9KnzDV98eKbg88D2zgKyY_GVq-IK4cwpq3ApmVVQHZ20G6_cSyVvbsc3d7cEOVVpoZalFAGFOo2fFcbG9u0riPX3ha1PNvfZCNU2C8dj5lXB2aevtM9BprQUEvuhENe--svD7i9F-8WutvDj5rAfLCkI1&t=638923853460000000"> 92 93</script>
93<script src="https://cdn.insight.sitefinity.com/sdk/sitefinity-insight-client.min.3.1.44.js" crossorigin="" async="async"> 94 95</script>
95<link href="/Telerik.Web.UI.WebResource.axd?d=PMrIT5dOWaVYIcpFWUE4nCGcRFDqtHj8a0dT9N7jtPAWgyp5t5fff0pvXeFargWg3kuRljuyyjKW8grLvrafOr9X0kIEdj24q9AbiZ0prs7qITvLoGQxdqYfpMFPSD250&t=638840910637275692&compress=0&_TSM_CombinedScripts_=%3b%3bTelerik.Sitefinity.Resources%2c+Version%3d15.3.8525.0%2c+Culture%3dneutral%2c+PublicKeyToken%3db28c218413bdf563%3aen%3ab494eb86-d40a-44e5-a7dc-aca57f5f48a3%3a7a90d6a" type="text/css" rel="stylesheet" /><title> 96 Speakers - Clinical Trial Innovation Summit 2018 97</title></head> <body><form method="post" action="./speakers" id="aspnetForm"> 98<div class="aspNetHidden"> 99<input type="hidden" name="ctl04_TSM" id="ctl04_TSM" value="" /> 100<input type="hidden" name="ctl05_TSSM" id="ctl05_TSSM" value="" /> 101<input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> 102<input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> 103<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="m0VS2enL7t5Z7Sej+/sNl8sdQG+K4S3SYSDpnrNwzStft+yJLBCImPwsblAl0QguwHDCrNEtUb95b+wdrZXxfJrjiUKjwZK/8q9RpfzXFGw=" /> 104</div> 105
106<script type="text/javascript"> 107//<![CDATA[ 108var theForm = document.forms['aspnetForm']; 109if (!theForm) { 110 theForm = document.aspnetForm; 111} 112function __doPostBack(eventTarget, eventArgument) { 113 if (!theForm.onsubmit || (theForm.onsubmit() != false)) { 114 theForm.__EVENTTARGET.value = eventTarget; 115 theForm.__EVENTARGUMENT.value = eventArgument; 116 theForm.submit(); 117 } 118} 119//]]> 120</script>
120 121 122
123<script src="/WebResource.axd?d=pynGkmcFUV13He1Qd6_TZA_YQJD9xSUnUi70uTXUUGkw9zf_LlVkiouvQJnBXeCn1svgT4yxk9LfN7iuqrWtXg2&t=639190689332169432" type="text/javascript"></script>
123 124 125
126<script type="text/javascript"> 127//<![CDATA[ 128var __cultureInfo = {"name":"en","numberFormat":{"CurrencyDecimalDigits":2,"CurrencyDecimalSeparator":".","IsReadOnly":true,"CurrencyGroupSizes":[3],"NumberGroupSizes":[3],"PercentGroupSizes":[3],"CurrencyGroupSeparator":",","CurrencySymbol":"$","NaNSymbol":"NaN","CurrencyNegativePattern":0,"NumberNegativePattern":1,"PercentPositivePattern":1,"PercentNegativePattern":1,"NegativeInfinitySymbol":"-â","NegativeSign":"-","NumberDecimalDigits":2,"NumberDecimalSeparator":".","NumberGroupSeparator":",","CurrencyPositivePattern":0,"PositiveInfinitySymbol":"â","PositiveSign":"+","PercentDecimalDigits":2,"PercentDecimalSeparator":".","PercentGroupSeparator":",","PercentSymbol":"%","PerMilleSymbol":"â°","NativeDigits":["0","1","2","3","4","5","6","7","8","9"],"DigitSubstitution":1},"dateTimeFormat":{"AMDesignator":"AM","Calendar":{"MinSupportedDateTime":"\/Date(-62135578800000)\/","MaxSupportedDateTime":"\/Date(253402300799999)\/","AlgorithmType":1,"CalendarType":1,"Eras":[1],"TwoDigitYearMax":2049,"IsReadOnly":true},"DateSeparator":"/","FirstDayOfWeek":0,"CalendarWeekRule":0,"FullDateTimePattern":"dddd, MMMM d, yyyy h:mm:ss tt","LongDatePattern":"dddd, MMMM d, yyyy","LongTimePattern":"h:mm:ss tt","MonthDayPattern":"MMMM d","PMDesignator":"PM","RFC1123Pattern":"ddd, dd MMM yyyy HH\u0027:\u0027mm\u0027:\u0027ss \u0027GMT\u0027","ShortDatePattern":"M/d/yyyy","ShortTimePattern":"h:mm tt","SortableDateTimePattern":"yyyy\u0027-\u0027MM\u0027-\u0027dd\u0027T\u0027HH\u0027:\u0027mm\u0027:\u0027ss","TimeSeparator":":","UniversalSortableDateTimePattern":"yyyy\u0027-\u0027MM\u0027-\u0027dd HH\u0027:\u0027mm\u0027:\u0027ss\u0027Z\u0027","YearMonthPattern":"MMMM yyyy","AbbreviatedDayNames":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"ShortestDayNames":["Su","Mo","Tu","We","Th","Fr","Sa"],"DayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"AbbreviatedMonthNames":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec",""],"MonthNames":["January","February","March","April","May","June","July","August","September","October","November","December",""],"IsReadOnly":true,"NativeCalendarName":"Gregorian Calendar","AbbreviatedMonthGenitiveNames":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec",""],"MonthGenitiveNames":["January","February","March","April","May","June","July","August","September","October","November","December",""]},"eras":[1,"A.D.",null,0]};//]]> 129</script>
129 130
131<script src="/Telerik.Web.UI.WebResource.axd?_TSM_HiddenField_=ctl04_TSM&compress=0&_TSM_CombinedScripts_=%3b%3bSystem.Web.Extensions%2c+Version%3d4.0.0.0%2c+Culture%3dneutral%2c+PublicKeyToken%3d31bf3856ad364e35%3aen%3add3ac3d5-1e29-4112-8fed-529caffa8f24%3aea597d4b%3ab25378d2" type="text/javascript"></script>
vendor: 2 bytes, line 131
131
132<script type="text/javascript"> 133//<![CDATA[ 134if (typeof(Sys) === 'undefined') throw new Error('ASP.NET Ajax client-side framework failed to load.'); 135//]]> 136</script>
136 137
138<script src="/ScriptResource.axd?d=xioHhidMnoH8GGW0PVBvnkvE_ocNtclJqLLfsNLXRjNdaA0pLSonPIl_WsgSt6V4yDfXSKj2RY3_12y81unZbVYi6xX685_9bfhDFh3N-__q7WJfPbf5Gc-oDb2EzXo0DUUUEUzlEyaLI0G1Su3_7GWKfdHCqx3i6Sr6D5HbXdDL-ChISrbHg0ksOjrnYkQW0&t=112ac451" type="text/javascript"></script>
vendor: 2 bytes, line 138
138
139<script src="/Telerik.Web.UI.WebResource.axd?_TSM_HiddenField_=ctl04_TSM&compress=0&_TSM_CombinedScripts_=%3b%3bTelerik.Sitefinity.Resources%3aen%3ab494eb86-d40a-44e5-a7dc-aca57f5f48a3%3a310a35a4" type="text/javascript"></script>
vendor: 2 bytes, line 139
139
140<script src="/Frontend-Assembly/Telerik.Sitefinity.Frontend/Mvc/Scripts/Bootstrap/js/bootstrap.min.js?package=Bootstrap&v=LTE4MzAzMTczMTU%3d" type="text/javascript"></script>
vendor: 2 bytes, line 140
140
141<script src="/js/sgs/menu-wsub.js" type="text/javascript"></script>
141 142<div class="aspNetHidden"> 143 144 <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="6099EC00" /> 145</div>
145<script type="text/javascript"> 146//<![CDATA[ 147Sys.WebForms.PageRequestManager._initialize('ctl00$ctl04', 'aspnetForm', [], [], [], 90, 'ctl00'); 148//]]> 149</script>
149 150<input type="hidden" name="ctl00$ctl04" id="ctl04" />
151<script type="text/javascript"> 152//<![CDATA[ 153Sys.Application.setServerId("ctl04", "ctl00$ctl04"); 154Sys.Application._enableHistoryInScriptManager(); 155//]]> 156</script>
156 157 158 159 160 161 162 163 164<div> 165 166 167 <div class="navbar navbar-default navbar-fixed-top"> 168 <a class="navbar-brand large" href="/"></a> 169 <div class="navbar-header"> 170 <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse"> 171 <span class="icon-bar"></span> 172 <span class="icon-bar"></span> 173 <span class="icon-bar"></span> 174 </button> 175 </div> 176 177 178 <div class="collapse navbar-collapse" id="bs-example-navbar-collapse-1"> 179 <ul class="nav navbar-nav large-nav" role="menu"> 180 <li class=""><a href="/archives" target="_self">Archives</a></li> 181 </ul> 182 </div><!-- /.navbar-collapse --> 183 </div> 184</div> 185 186 187 188 189 190 191 192 193 194 195<div > 196 <div class="sf-Long-text" ><!-- Mobile Banner --> 197<div class="mobile-header hidden-sm hidden-md hidden-lg"><a href="/"><img alt="" class="imageResize" src="/images/librariesprovider49/template-images/20/header-mob.png" /></a> 198</div></div> 199</div>
vendor: 70 bytes, lines 199-202
199 200 201 202<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=
202GTM-KC9X826
vendor: 93 bytes, lines 202-212
202" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> 203 204 205 206 207 208 209 210 211 212
212<div class="main-content"> <div id="cph1" class="container internal"> <div class="row"> 213<div class="row" data-sf-element="Row"> 214 <div class="col-sm-9"> 215 <div id="Contentplaceholder1_TEE75556F001_Col00" class="sf_colsIn pad-lr" data-sf-element="Column 1" data-placeholder-label="Column 1"> 216<div > 217 <div class="sf-Long-text" ><p class="pageTitle">Speaker Biographies</p><p class="Session"><a href="#1">Budgeting & Outsourcing </a></p><p class="Session"><a href="#2">Data & Technology</a></p><p class="Session"><a href="#3">Engagement & Enrollment</a></p><p class="Session"><a href="#4">Feasibility & Site Selection</a></p><p class="Session"><a href="#5">Risk-Based Monitoring</a></p><p class="Session"><a href="#6">Interactive Roundtable Breakout Discussions </a></p><p class="Session"><a href="#7">Plenary</a></p><hr /><br /><a id="1"></a><p class="Header">Budgeting & Outsourcing </p><p><strong>Debora Araujo, Founder & CEO, ClinBiz</strong> <strong></strong><br />Débora S. Araujo has over a decade of experience in the pharmaceutical industry working and consulting for Fortune 500 companies. During her time in this industry 218 her special focus has been on the business aspects of clinical trials including: clinical contracting and financial management, clinical outsourcing and CRO/vendor management, global clinical trial budgeting and forecasting, clinical financial analytics 219 and metrics/KPIs, site budget development and negotiations, Fair Market Value (FMV) and global investigator site payments. She has also utilized her expertise and knowledge to drive practical change in this industry via thought leadership material, 220 conference presentations and consulting engagements. Débora’s passion for driving practical change in the industry led her to launch ClinBiz (www.clinbiz.com), an online platform with a dedicated YouTube channel, podcast, blog and much 221 more where clinical research professionals can stay connected and updated on the latest topics, trends and technologies related to the business aspects of clinical trials. Débora has also recently published a book on clinical trial agreement 222 negotiations named ‘The Four Villains of Clinical Trial Agreement Delays and How To Defeat Them’ which quickly became an Amazon’s #1 New Release in the pharmaceutical and biotechnology category.</p><p><strong>Chuck Bradley, Vice President, Clinical Development, FibroGen, Inc. </strong><br />Charles Bradley is VP Clinical Development and Head of Clinical Operations at FibroGen Inc. located in San Francisco, CA. Dr. Bradley is an experienced clinical 223 research professional with an in-depth background in all phases of drug development. He is a seasoned senior manager with knowledge of resource allocation, portfolio management, budgetary processes, outsourcing strategies, and regulatory requirements 224 associated with drug development. He has expertise in driving clinical programs forward in entrepreneurial environments, smaller biotech companies, and large traditional pharmaceutical companies. Chuck received his Ph.D. in bioanalytical chemistry 225 from the University of Delaware, received post-doctoral training in Clinical Pharmacology at Uniformed Services University, and is Board Certified in Applied Pharmacology.</p><p><strong>Marina Malikova, PhD, Executive Director, Surgical Translational Research: Operations and Compliance, Boston University School of Medicine </strong> 226 <br />Marina Malikova, PhD, MSci, MA, CCRA, RAC Executive Director, Surgical Translational Research: Operations and Compliance. Dr. Malikova has over 14 years of experience in the clinical research field. She has managed Phase I – IV studies 227 involving investigational drugs, devices and biologics. She has worked on Industry-sponsored and Investigator-initiated trials in the fields of Surgery, Cancer Diagnostics and Interventional Radiology. Dr. Malikova graduated from the Institute of 228 Biochemistry, Russian Academy of Science, in Moscow, Russia with a PhD in Biochemistry. She has a strong background in biomedical sciences and has completed her postdoctoral fellowship in the field of cell signaling and cell migration. She also holds 229 a Master’s Degree in Clinical Investigation, Certification in Project Management from Boston University and board certified in Regulatory Affairs (RAC). In her current role as Executive Director, Dr. Malikova manages research efforts in 13 divisions 230 of the Department of Surgery at Boston Medical Center. She is responsible for clinical trials and basic biomedical research operations, quality assurance, risk management, strategic planning, and macro-management of research programs. She advises 231 faculty/staff on protocol and informed consent writing; assists with BU IRB applications and submissions; provides oversight for data user agreements, cost coverage analysis and budgets development, contracts and licensing for clinical research; and 232 ensures compliance. Dr. Malikova has 12 years of teaching experience as an Instru
232ctor for Clinical and Biomedical Sciences Program, Metropolitan College. She has developed and taught several courses such as: Design and Conduct of Clinical Trials, 233 Drug Development, Introductory Pharmacology, Clinical Trials Management at Boston University, School of Medicine. She also serves as an Instructor of the Good Clinical Practices (GCPs) course for the Master of Science Program in Clinical Investigation, 234 Division of Graduate Medical Sciences, Boston University, School of Medicine. Dr. Malikova is a member of Association for Clinical Research Professionals (ACRP), Drug Information Association (DIA), Regulatory Affairs Professionals Society (RAPS) and 235 European Society of Radiology (ESR).</p><p><strong>Cameron McClure, PMP, PMI-ACP, CSM, CCRP, Senior Manager, Clinical Business Operations, BeiGene</strong><br />Cameron McClure is a California native and Senior Manager of Clinical Business Operations at BeiGene, Ltd. He is a certified Project 236 Management Professional with a demonstrated history of working in the pharmaceutical and higher education industry. He finished his Bachelor’s Degree in Communication from California State University, Fresno and is currently pursuing his Master 237 of Science Degree in Clinical Research Management (Regulatory Affairs) from Arizona State University. Outside of work, he enjoys music, fitness, fatherhood, and spending time with family and friends. </p><p><strong>Scott Sawicki, R&D Sourcing Consultant, Adare Pharmaceuticals</strong><br />Scott Sawicki is an R&D Sourcing Consultant at Adare Pharmaceuticals. He has over 25 year’s career experience having predominantly worked in senior positions 238 for large multi-national corporations, mostly as a R&D Sourcing professional. His varied industry experience with both sponsors and CROs includes R&D Sourcing, Supplier Relationship Management and Business Development, with sponsor companies 239 Adare Pharmaceuticals, Novartis Pharmaceuticals, Aventis, and CROs Syneos Health and Covance. In 2018, Scott joined Adare Pharmaceuticals as an R&D Sourcing consultant, leading Adare’s R&D team in selecting, negotiating, contracting 240 and providing business oversight and strategic insights of CROs and other suppliers in support of Adare R&D efforts, including Medical Affairs.</p><p><strong>Mai Nguyen, MPH, Senior Consultant, The Avoca Group </strong><br />No Bio Available</p><a id="2"></a><p class="Header">Data & Technology</p><p><strong>Jay Bergeron, Director, Pfizer Digital, Pfizer </strong><br />Jay Bergeron is Director, Digital Client Partner for Early Clinic Development and Integrative Biology at Pfizer. He served as the Scientific Coordinator of IMI-eTRIKS, a $30M Public 241 Private Partnership for building open source translation research information management systems.</p><p><strong>DonBerry, PhD, Professor, Biostatistics, University of Texas M.D. Anderson Cancer Center </strong><br />Donald Berry is Founder of Berry Consultants, LLC, and a professor in the Department of Biostatistics of the University of Texas M.D. Anderson 242 Cancer Center. He was founding Chair of this department in 1999. Dr. Berry received his PhD in statistics from Yale University, and previously served on the faculty at the University of Minnesota and at Duke University. He has held endowed faculty 243 positions at Duke University and M.D. Anderson. Dr. Berry is a well-known developer of statistical theory and methodology. He has designed and supervised the conduct of hundreds of innovative clinical trials, including Bayesian adaptive trials in 244 cancer and other diseases. He is a Fellow of the American Statistical Association, the Institute of Mathematical Statistics, and the International Society of Bayesian Analysis. </p><p><strong>MattDe Silva, Founder and CEO, Notable </strong><br />Matt De Silva’s connection to Notable is an especially personal one. He founded the company in 2014 to give his father a fighting chance against brain cancer. Adopting precision medicine 245 from the beginning, Notable went on to develop a clinically-validated platform to rapidly identify and advance cancer therapeutics at a fraction of the traditional time and cost. Previously Matt served as a portfolio manager and trader at Clarium 246 Capital, a global macro hedge fund. Matt started his career on a foreign exchange and interest rate sales and trading desk at Bank of America Merrill Lynch. Matt received his BA magna cum laude in Applied Economics and Management from Cornell University.</p><p><strong>Eric Gildenhuys, Vice President, Business Development, Deep 6 AI </strong><br />Eric is responsible for developing and executing on the sales strategy for Life Sciences, Pharma, CROs, and Partnerships for Deep 6 AI. Eric has 25 years’ 247 experience helping companies improve their revenue streams. He began his career by co-founding and selling a software company to Optio Software, helping guide Optio to a
247successful IPO by expanding into the healthcare market and launching its European 248 headquarters. For the last 14 years, Eric has been helping software and professional services firms such as PwC all over the world in shifting the paradigm of their business development culture, resulting in new contracts worth $100+ million.</p><p><strong>JudithKornfeld, Chief Business and Operations Officer, ORCATECH, Oregon Health and Sciences University </strong><br />Judith Kornfeld, MBA, is the Chief Business and Operations Officer of ORCATECH. Through building worldwide strategic collaborations 249 and alliances while positioning Intellectual Property assets and leveraging products in development, Ms. Kornfeld specializes in bringing innovative medical technologies to prosper in the medical industry. Prior to joining ORCATECH she assumed executive 250 business development positions of emerging medical technological companies in the specialty pharmaceuticals and medical device industries. Recently, Ms. Kornfeld held the position VP of Business Development of TransPharma Medical, a company focused 251 on developing pharmaceutical products based on breakthrough proprietary transdermal drug-delivery technology. Ms. Kornfeld holds a bachelor's degree in life sciences and an MBA, as well as an academic background in electrical engineering.</p><p><strong>Jake LaPorte, Co-Founder & Global Head of the Novartis Biome, Novartis </strong><br />Jake LaPorte, PhD, is Global Head of Digital Development at Novartis and responsible for leading the company’s digital efforts within their Global 252 Drug Development organization. Jake began his career at McKinsey & Company, where he was a leader in their Pharmaceutical R&D practice, during his six-year tenure, developing an expertise in large, complex transformations and innovation. It 253 was on a fateful, extended journey in Asia-Pacific, however, where Jake read Ray Kurzweil’s The Singulatiry is Near and became captivated by the possibility of digitalizing the Pharmaceutical R&D engine – he has focused his career 254 to the realization of this concept ever since. He co-founded Snapdragon Chemistry, with the Head of the Chemistry Department at MIT, which seeks to enable companies to implement continuous flow chemistry in discovery, development and manufacturing, 255 with the ultimate goal of fully digitalizing chemical synthesis. Most recently, Jake has held various leadership positions at PPD, Inc., where he collaborated with executives to develop and implement C-level, strategic initiatives, including a long-term 256 transformation to create industry-leading approaches to clinical development in key therapeutic areas. Jake completed his Ph.D. in Organic Chemistry from Harvard University, where he was an HHMI doctoral fellow, and received his B.Sc. in Biochemistry 257 and Mathematics, summa cum laude, from the University of Delaware.</p><p><strong>Ijah Mondesire-Crump, MD, Research Director, nQ Medical Inc </strong><br />Physician scientist conducting and supporting cutting-edge research (basic and clinical) in the fields of oncology, immunology and neurology. Established record leading 258 translational research at a world-renown oncologic clinical research organization. Significant experience conducting clinical trial recruitment and consenting. Dedicated to exceeding performance benchmarks. Passionate and knowledgeable about health 259 policy and design, and dedicated to driving more effective, system-wide healthcare management, research, pharmacologic therapeutics and biotechnologies. </p><a id="3"></a><p class="Header">Engagement & Enrollment</p><p><strong>Jonathan Andrus, Chief Business Officer, Clinical Ink</strong> <strong></strong><br />"As Chief Business Officer, Jonathan Andrus leads Clinical Ink’s solution management and compliance teams to help sponsors and CROs better leverage eSource, 260 eCOA and ePRO data. With more than twenty years of experience, Mr. Andrus brings extensive expertise developing eClinical services that integrate data and technology to help life science companies optimize study execution. At Clinical Ink, Mr. Andrus 261 is responsible for P&L across Clinical Ink’s products and services, and he is also focused on building relationships and forging strategic partnerships with sponsors, CROs, regulatory bodies and clinical research professionals. Mr. Andrus 262 joined Clinical Ink from BioClinica where he led the eClinical Solutions Group to develop their current service offerings, including data management, quality management, implementation services and IWRS. Prior to BioClinica, Mr. Andrus worked in pharmaceutical 263 consulting and with CROs focused on quality, data management and validation. An active thought leader, blogger and presenter, Jonathan served as chair of the Society for Clinical Data Management (SCDM) in 2008 and 2013 and currently serves as the 264 society’s Treasurer. He is also an active member of DIA (North American Advisory Council and Annual Conference Data/Data Standards Track Chair) and ASQ. He earned his bachelor’s and master’s degrees from Temple University’s 265 College of Liberal Arts and Graduate School of Pharmacy and is a Certified Quality Auditor (CQA) and Certified Clinical Data Manager (CCDM®).</p><p><strong>Bonnie Brescia, Founding Principal, BBK Worldwide</strong> <br />Bonnie A. Brescia is a founding principal of BBK Worldwide, and a leader in patient recruitment and engagement for more than 35 years. Widely recognized for helping to shape the 266 recruitment discipline and a preeminent voice for patient centricity, her insights regarding the global clinical research community inform the industry and help fuel BBK’s leadership, innovation and global expansion. She leads the company’s 267 involvement in its efforts dedicated to global excellence in clinical research, and was recently honored by the Boston Globe Magazine with a Top 100 Women-led Business award. Bonnie speaks at several industry events and conferences each year, and 268 has conducted many forums on strategies for clinical trial marketing to diverse audiences. She is frequently quoted in the media on a broad range of industry topics including patient centricity and mHealth and was named to the PharmaVOICE 100 for 269 her leadership. A mother of two daughters and mentor to many young professionals, Bonnie is committed to equal opportunities for diverse perspectives in business and community life.</p><p><strong>Richard Brescia, Clinical Trial Participant<br /></strong>Richard spent his career in broadcasting. In June 2016, he was diagnosed with an advanced and aggressive head and neck cancer. After interviewing several specialists working in research 270 hospitals in New York and Connecticut, he and his family began their treatment journey with a team of p
270hysicians and surgeons at the Smilow Cancer Center of Yale University Hospital. Nearly three years later, Richard has participated in three clinical 271 trials — including interventional and pharmacokinetic studies. </p><p><strong>Joan Chambers, Senior Director, Marketing & Outreach, CISCRP </strong><br />Joan develops and executes strategic marketing, promotional and outreach campaigns to support CISCRPs mission of raising awareness and understanding about clinical 272 research and the important role it plays in public health. Additionally, directs, plans, launches new initiatives for new growth opportunities. A well-known speaker at industry conferences, Joan has presented on a wide variety of topics specific to 273 the clinical trials enterprise. Joan is on the Board of Directors for Greater Gift, the US PharmaTimes Steering Committee for CROY, Steering Committee for Pharma Intelligence/ Informa Clinical & Research Excellence Awards (CARE), Steering Committee 274 for PopUp Star and is an active member of the Association of Clinical Research Professionals (ACRP) and the Drug Information Association (DIA). Joan was on the Advisory Board for The Center for Information and Study on Clinical Research Participation 275 (CISCRP) for over 10 years. In the course of her career, she has published in clinical trade journals and was an instructor for Barnett International’s CRA/CRC programs on the site identification/qualification process. Accomplished and performance-driven 276 marketing and operations executive with 20+ years of experience in the health life sciences with a successful track record in marketing and strategic planning, implementation, guidance and direction to companies and professionals. Ability to lead, 277 motivate, mentor and establish strong relationships at all levels internally and externally. Strong professional networking and presentation skills among a wide range of industry business professionals. Joan was formerly COO at CenterWatch. Her career 278 included roles at ClinX, SCORR Marketing, CHI, Tufts CSDD and PAREXEL. Joan holds a B.S. in Marketing.</p><p><strong>Cathy Critchlow, PhD, Vice President, Center for Observational Research, Amgen, Inc.</strong> <strong></strong><br />As Head of the Center for Observational Research (CfOR), Dr. Critchlow provides operational and strategic leadership for the 279 design and conduct of observational research within Amgen. The CfOR Real World Data (RWD) Platform provides widespread access to patient health data and visualization and analytic tools based on innovative technologies to aid teams in the generation 280 of rea- world evidence in support of Amgen products. Prior to joining Amgen in 2004, Dr. Critchlow was a faculty member in Epidemiology at the University of Washington. Dr. Critchlow earned her bachelor’s degree from Stanford University, and 281 both her master’s degree in biomathematics and her doctorate degree in epidemiology from the University of Washington.</p><p><strong>Emma D’Agostino, CF Patient, Patient Advocate, Member of FDA Review Committee, Patient Advocate </strong><br />Ms. D'Agostino was diagnosed with cystic fibrosis at birth. She graduated from the University of North Carolina at Chapel Hill 282 with degrees in biology and chemistry (Go Heels!) and is pursuing her doctorate in biochemistry at Emory University in her hometown of Atlanta. Ms. D'Agostino is a member of the Data Safety Monitoring Board and co-chair of the Research Summary Review 283 Committee at the Cystic Fibrosis Foundation, as well as the consumer representative for the Pulmonary-Allergy Drugs Advisory Committee at the FDA.</p><p><strong>Annick de Bruin, MBA, Director, Research Services, Center for Information & Study on Clinical Research Participation (CISCRP) </strong><br />Annick de Bruin is the Director of Research Services at CISCRP. She is responsible for the design, 284 implementation, analysis and reporting of a variety of CISCRP research studies including the Perceptions & Insights studies and numerous Patient Advisory Boards. She has more than 20 years of experience conducting primary and secondary research 285 studies in the healthcare, life sciences and consumer goods industries. She holds an MBA from the Graduate School of Management at Boston University and a Bachelor of Science degree from Bryant University.</p><p><strong>Rose Gerber, Director, Patient Advocacy and Education & 3x clinical trial participant, Community Oncology Alliance (COA)</strong> <br />Rose Gerber is a nationally recognized cancer advocate and cancer survivor. Her experience includes appearing 286 on national television (MSNBC) to speak about cancer care, meeting with legislators in Washington, DC on cancer policy issues, and developing cancer programs. Rose was brought to the COA team to develop its patient advocacy program. One of her first 287 accomplishments was to add an advocacy track to the annual conference, making the meeting one of the few that brings together physicians, administrators, and advocates. She serves as an invited member on national patient advocate panels, steering
288 committees, and cancer coalitions. Rose has also served as a consumer reviewer on the Congressionally Directed Medical Research Programs – Department of Defense Breast Cancer research panels.</p><p><strong>Phyllis Kaplan, Trial Volunteer and Patient Advocate; Senior Project Manager, Health Communication Services, Center for Information & Study on Clinical Research Participation (CISCRP)</strong><br />Phyllis Kaplan is a Senior Project Manager 289 on the Health Communication Services team at CISCRP, focusing on plain language summaries of clinical trial results. When not in the office, she volunteers most of her time as an advocate in the diabetes community and running educational programs 290 for adults with type 1 diabetes. She holds a Master’s degree from Teachers College, Columbia University, and a Bachelor of Science degree from Long Island University.</p><p><strong>Michael Keens, Chief Operating Officer, Firma Clinical</strong> <br />Michael Keens serves as the Chief Operating Officer for Firma Clinical Research, a niche service provider specializing in data analytics and clinical home care for clinical 291 trials. In his role as COO, Mike specifically oversees Firma’s Clinical Home Care services, working with Sponsors to implement home nursing services in clinical trials to reduce patient burden in clinical trials and facilitate “bringing 292 the trial to the patient.” Additionally, Mike leads Firma’s partnership efforts with Patient Advocacy organizations of all size (e.g., Alzheimer’s Association, National MS Society, Scleroderma Foundation, etc.), facilitating the 293 introduction of these organizations to Pharmaceutical companies, and increasing their involvement within clinical trials to enhance patient benefit. Mike earned his B.S.in Biology/Psychology (double-major) from James Madison University, and his M.S. 294 in Health Evaluation Sciences from The University of Virginia. An accomplished clinical trials professional with over 20 years of experience across multiple healthcare and drug development organizations, Mike has proven success in clinical operations, 295 project management, business development and executive leadership. </p><p><strong>Mary Jo Lamberti, PhD, Associate Director and Research Assistant Professor, Tufts Center for the Study of Drug Development (CSDD) </strong><br />Dr. Mary Jo Lamberti manages multi-sponsored and grant funded research projects at Tufts CSDD. She 296 has extensive experience conducting market research on pharmaceutical industry practices and trends affecting contract research organizations and investigative sites. She has been a speaker at conferences and has published articles in trade and peer-reviewed 297 journals. Prior to joining Tufts CSDD, Dr. Lamberti was director of market research at CenterWatch. She has also worked on federally funded research studies in science education reform. Dr. Lamberti holds a BA from Wellesley College and a PhD in psychology 298 from Boston University.</p><p><strong>Angela Lee, Associate Director, Data Management, Otsuka </strong><br />Ms. Lee has been working in clinical data management for 19 years. She is currently the Associate Director of Data Management at OTSUKA Pharmaceuticals. She earned her BS 299 in Biology from Yale University and continued her studies at Yale School of Epidemiology and Public Health, where she earned her MPH. She spent over a decade working at CROs where she managed and streamlined processes and systems, including a global 300 harmonization of SOPs. At Otsuka, Ms. Lee has been integral at managing and scaling up the ePlatform model for clinical data operations, working on processes integrating eConsent, IRT and eSource. </p><p><strong>Christina Roman, MPH, Senior Manager of Community Engagement, Community Partnerships, Cystic Fibrosis Foundation</strong> <br />Christina Román is the Sr. Manager of Community Engagement at the Cystic Fibrosis Foundation in Bethesda, MD. 301 In this role, she works on a range of projects at CFF which include managing patient engagement activities across the Foundation. Her work includes overseeing the community groups who contribute to CF research and care initiatives, insights research 302 in the CF Community and overseeing the development of tools to help improve patient engagement. Christina earned her Masters in Public Health in 2013 from the University of Colorado, Denver.</p><p><strong>Hollie Schmidt, Vice President, Scientific Operations, Accelerated Cure Project for MS</strong><br />Hollie Schmidt is the Vice President of Scientific Operations at Accelerated Cure Project for Multiple Sclerosis. She co-chairs the Research 303 Committee of iConquerMS, a participatory research network for MS established to perform and support patient-centered research in MS. In this role she works to promote patient engagement throughout the research process and to develop research collaborations 304 on topics of interest to people with MS. She founded and leads the MS Minority Research Engagement Partnership Network, a multi-stakeholder initiative aimed at promoting racial and ethnic diversity in MS research studies. Before joining Accelerated 305 Cure Project, Ms. Schmidt's endeavors included co-founding a management consulting firm and two software companies. Ms. Schmidt has an MS in Management, as well as a BS and MS in Materials Science and Engineering, all from the Massachusetts Institute 306 of Technology. She also serves on the Institutional Review Board of Beth Israel Deaconess Medical Center and is Secretary for the Multiple Sclerosis Coalition. </p><p><strong>Leah Szumita, MSN, Associate Director, Nursing, Clinical Trial Support Center, The Leukemia & Lymphoma Society, Beat AML/LLS </strong><br />In her role as Associate Director of Nursing in the Clinical Trial Support Center, Leah Szumita supports 307 The Leukemia & Lymphoma Society’s (LLS) efforts to educate and support patients and caregivers affected by blood cancers. Through education, advocacy, coaching and decision-support services, Szumita and the team of nurses help patients and 308 their caregivers navigate the process of identifying and participating in clinical trials, and provide support through the continuum of their treatment and care. Prior to joining LLS, Szumita was staff nurse in the Medical Intensive Care Unit at Brigham 309 and Women’s Hospital in Boston, MA where she later became a Clinical Nurse Specialist and Clinical Nurse Educator. Szumita is certified as an Adult Health Critical Care Clinical Nurse Specialist, Critical Care RN and gerontology RN. She graduated 310 from Saint Anselm College with a Bachelor of Science in Nursing and obtained her Master of Science in Nursing at the University of Massachusetts Boston. </p><a id="4"></a><p class="Header">Feasibility & Site Selection</p><p><strong>
310Rick Arlow, CEO, Complion, Inc.</strong> <br />Drawing on his engineering background, and inspired by his work in clinical research, Rick Arlow built the first version of the Complion software platform. In close collaboration with leading medical 311 centers, Complion’s industry-leading workflow and document management software was born. Since then, Rick has built a world-class team experienced in clinical research. He is a frequent lecturer for several professional research organizations 312 including ACRP, MAGI and SCRS. </p><p><strong>Christina Brennan, MD, MBA, Vice President, Clinical Research, Northwell Health</strong><br />Christina Brennan, MD has devoted her career to clinical research and currently serves as Northwell Health’s vice president of clinical research. 313 <br />Committed to the advancement of science and medicine, Dr. Brennan has more than 19 years of extensive clinical research experience, including over 14 years in clinical research management roles. She is the immediate past president of the NY 314 Metropolitan Chapter of the Association of Clinical Research Professionals. She also is on the advisory board of the Weschester Biotech project. She is an active member of the Clinical Trial Transformation Initiative (CCTI), with Duke University and 315 the FDA, where she actively sits on some of their committees. She also sits on the oncology advisory board and technology site advocacy group with the Society for Clinical Research Sites (SCRS). She is also an active member of the Drug Information 316 Agency, the Regulatory Affairs Professional Society, Women in Bio and the American College of Healthcare Executives. "</p><p><strong>Marie Elena Cordisco, MA, APRN, NP-C, Nuvance Health</strong>; Director Clinical Trials, Western Connecticut Health Network; Interim Director, Division of Research, Health Quest </p><p><strong>Cayce Drobek, Director, Clinical Operations, Teckro <br /></strong>Cayce brings more than a decade of clinical research experience, working at sponsor companies, CROs, and investigative clinical trial sites. Cayce has worked on numerous Phase 317 I-IV trials across therapeutic areas. She has undergraduate degrees in Biology and Mental Health and holds two Master’s Degrees in Microbiology and Clinical Research.</p><p><strong>Gabriela Feldberg, Practice Leader, Applied Analytics & Artificial Intelligence, AstraZeneca </strong><br />Gabriela has spent 20 years in various roles across both pharma and CROs with much of her recent focus spent on building and leading 318 highly effective global feasibility, site selection and patient engagement organizations. Gabriela’s current role as Practice Leader within the Data Science and Artificial Intelligence organization has continued to refine this mission with an 319 additional emphasis on extracting maximum value for our patients by leveraging data science to provide valuable insights to better select investigators for clinical studies. Previously she has led global Feasibility, Site Selection and Patient Engagement 320 groups at Covance and UCB. Prior to UCB, Gabi spent over ten years at Quintiles where she held positions of increasing responsibility. Gabi also held positions at Kimberly-Clark and Cordis earlier in her career. Gabi received her B.S. Degree in Chemistry 321 from the University of Florida.</p><p><strong>Kaitlin Folweiler, PhD, Data Scientist, R&D Data Science, Analytics and Insights, Janssen</strong> <strong></strong><br />Kaitlin Folweiler is Data Scientist in Data Science Analytics and Insights at Janssen Research & Development. Kait 322 received her PhD degree in Neuroscience from the University of Pennsylvania in Philadelphia where she developed her skills in machine learning. In her current role, Kait utilizes her interdisciplinary skills in neuroscience and data science to bring 323 insights and impact projects across the R&D organization, such as predictive analytics for complex biological problems and transforming clinical trials.</p><p><strong>Jane Hart, Vice President, Global Clinical Affairs, 3M Health Care</strong> <br />
323Jane Hart has worked in the Clinical Research Industry for over 22 years. In her current position with 3M she leads the Global Clinical Development organization. 324 Her team is focused on generating evidence to support the safe and effective use of KCI products primarily through company sponsored and investigator sponsored research. Jane started her career in Australia working in breast cancer research and relocated 325 to the US 17 years ago. She is experienced in executing pre and post market studies globally for both drug and devices. Highlights of studies she has managed include FDA approval of a nanocoated cardiac stent, hormonal therapy for breast cancer and 326 chemotherapy for hematological malignancies. </p><p><strong>Amanda Hayden, Clinical Trial Manager, Global Clinical Services, Alkermes </strong><br />Amanda Hayden is a Senior Director of Global Clinical Services at Alkermes, Inc, and has worked for 20 years in the clinical operations field. Amanda started 327 her career as a CRA with a small CRO, progressing to Project Management roles at Antigenics (now Agenus), Millennium Pharmaceuticals (now Takeda), and Lantheus Medical Imaging. In her role at Alkermes, Amanda oversees the Study Start Up, Clinical 328 Compliance and Clinical Systems and Disclosure teams. She has extensive prior monitoring and project management experience, with more than 10 years focused on Oncology trials. In the last 5 years, Amanda has spent significant time dedicated to large 329 scale CNS trial start-up, including global trial submissions and launches in approximately 20 countries, as well as in overseeing ICH E6 R2 implementation and Inspection Readiness initiatives.</p><p><strong>Justin Hensperger, MS, Site Intelligence Lead – Associate Director Internal Medicine, Pfizer</strong> <br />Justin Hensperger is an Associate Director, Site Intelligence Lead for internal medicine for Pfizer Inc. Justin studied medical 330 laboratory science at University of Delaware, and a Master’s in clinical trial science from Rutgers. He began his career in pharma working at a CRO as a feasibility analyst before moving to the sponsor side. As a Site Intelligence Lead he is 331 working on improving the way we utilize data to drive site selection, and ensuring that we select the right sites the first time for our studies.</p><p><strong>Marcy Kravet, BS, MBA, Head, Operational Design Center, EMD Serono</strong> <br />Marcy Kravet is an Operations leader with a history of creating and implementing functions that drive efficiency and innovation in planning and execution. In 2018 332 Marcy joined EMD Serono to create the Operational Design Center (ODC) within Global Clinical Operations. Prior to joining EMD Serono, Marcy spent 12 years at Bristol-Myers Squibb in patient recruitment, late stage development, medical affairs scientific 333 publications, and early development. Marcy also has experience working at a primary care research network and a patient recruitment vendor. </p><p><strong>Hugh Levaux, Founder and CEO, Protocol First</strong> <br />Dr. Hugh Levaux is Founder CEO of Protocol First. The company offers innovative software solutions for clinical research.&nbsp;&nbsp;Leading products are P1 EDC, a full eClinical 334 research platform and Clinical Pipe, the industry&rsquo;s first system-agnostic EHR-to-EDC connector application. Dr. Levaux has over 2 decades of clinical research experience.</p><p><strong>Brandon Maggio, Associate Director, Global Clinical Operations, Boehringer Ingelheim</strong><br />Brandon has worked in the industry for 15+ years and joined Boehringer Ingelheim in 2011. During his tenure at BI, he managed multiple pivotal 335 Phase 3 trials within the Metabolic, CNS, Cardiovascular, and Respiratory therapeutic areas. In 2018, he took on the role of Global Clinical Operations Integration Lead for Decentralized Clinical Trials. This position coordinates all other supporting 336 trial enabling functions, as well as, facilitation of educational and change management activities for BI’s clinical research ecosystem.</p><p><strong>Beth Mahon, Global Feasibility Therapeutic Area (TA) Head, Feasibility Center of Excellence (FCoE), Clinical Insights and Experience, Oncology, Janssen</strong> <br />Beth Mahon, Global Feasibility Therapeutic Area Head for Solid Tumor Oncology, 337 is part of the Global Feasibility Center of Excellence at Janssen R&D. She works to enhance program and protocol strategies for better and more cost effective scientific and regulatory outcomes while balancing customer-focused insights and data 338 analytics in early planning and execution of clinical trials. Beth has over 19 years of clinical operations experience joined Janssen in 2007. </p><p><strong>Sylvia Marecki, PhD, Design Analyst, EMD Serono </strong><br />Sylvia Marecki joined the Operational Design Center within Global Clinical Operations at EMD Serono in 2019. Prior to joining EMD Serono, Sylvia led development and commercialization 339 of products and services at Citeline/Informa, Decision Resources Group, and TriNetX, empowering data-driven decisions across clinical and commercial functions. She received her Doctorate in Pathology and Immunology from Boston University School of 340 Medicine.
341 <br /><strong></strong><br /><strong>Len Rosenberg, PhD, RPh, Head, Clinical Operations, The Leukemia & Lymphoma Society, Beat AML/LLS </strong><br />Dr. Rosenberg is a 30 plus year executive with proven experience in driving operational excellence 342 at all levels within the pharmaceutical, biotechnology, eclinical and contract research organization sectors. With his diverse background which includes executive management, clinical and regulatory operations, business development, eclinical technology 343 solutions and new product/licensing evaluations, he brings tremendous hands on insights to optimizing the drug development cycle, from the early start-up stage to global product registration. Dr. Rosenberg is Head, Clinical Operations at Beat AML, 344 LLC, a division of The Leukemia & Lymphoma Society and also Managing Partner of eP2Consulting, Inc. since 2001.</p><a id="5"></a><p class="Header">Risk-Based Monitoring</p><p><strong>Muhammad Ali, Central Monitoring, Pfizer</strong> <br />Muhamad Ali started his career as a Business/Quality Assurance Analyst. One of the key contributors on Pfizer’s RBM implementation team, managed formalization of Pfizer’s business 345 process for RBM implementation. Currently working as a Sr. Central Monitor for Pfizer and responsible for coordinating with study teams to align on FDA ICH ICHE6 R2 guidelines</p><p><strong>Linda Sullivan, Co-Founder & Executive Director, WCG - Metrics Champion Consortium</strong><br />Linda B. Sullivan is Co-Founder & President of the Metrics Champion Consortium (MCC), an industry association dedicated to leading the drug-development 346 enterprise in the adoption and utilization of standardized metrics and benchmarks to drive performance improvement. She has been a featured speaker at Performance Metrics, Risk-Based Monitoring, Quality Management & Clinical Trial Oversight industry 347 meetings. Ms. Sullivan received a BS in Biology from Trinity College and a MBA from Dartmouth College where she was named a Tuck Scholar. </p><p><strong>Lucien Agnant, Technology Integration Specialist, Clinical Management, Otsuka Pharmaceutical Development & Commercialization, Inc. </strong><br />Lucien Agnant has spent the last two decades impacting the health of patients through direct 348 patient care and research and development. While working at Otsuka, Lucien has held positions in Clinical Safety and Pharmacovigilance, Program Management, and most recently Clinical Management. Lucien has worked on multiple medicines across a variety 349 of therapeutic areas including cardiovascular, neuroscience, nephrology, ophthalmology, dermatology, respiratory and oncology. In his current role, Lucien leads the technology integration group which focuses primarily on the integration of paperless 350 systems (eSource, eConsent, eScanning). </p><p><strong>Kevin Douglass, Associate Director, Process Excellence & Risk Management, Daiichi Sankyo, Inc. </strong><br />Kevin is an Associate Director in Process Excellence & Risk Management at Daiichi-Sankyo. The Process Excellence & Risk 351 Management (PERM) Team partners within Clinical Operations and with other functional areas to optimize clinical trial processes and tools, with a specific focus on risk-based quality management (including risk assessment, risk-based/centralized monitoring, 352 and metrics oversight). PERM members are assigned to study teams and lead process improvement projects, usually in collaboration with CRO partners. Kevin has more than 30 years industry experience working for numerous companies (Wyeth, Rhone-Poulenc 353 Rorer, Pfizer, and Shire) in various positions (Data Management, Database Programming, Quality & Compliance, and Operational Excellence). During that time, he was certified in Lean Six Sigma/Change Management and led multiple cross-functional 354 continuous improvement projects. He received his BS in Biology from Ursinus College and MS in Biology from Villanova University. Kevin currently resides in New Jersey with his wife and spends most of his free time with their three daughters and 2 355 grandchildren. He can be contacted at [email protected].</p><p><strong>Laura Galuchie, TransCelerate Program Lead, Oversight Committee, Merck & Co., Inc.; TransCelerate Biopharma Inc. </strong><br />
355Laura has a unique role which blends internal and external components. Laura is Merck & Co., Inc.’s 356 assigned leadership to the Oversight Committee of TransCelerate BioPharma Inc. The Oversight Committee is the primary governing body for decisions related to the operational direction of TransCelerate, including project direction and expected outcomes. 357 Laura draws on her experience as Director of Clinical Operations for a busy therapeutic area and Head of Clinical Performance, Analytics and Innovation to provide this perspective. Within Merck, she has responsibility for driving internal engagement 358 with key stakeholders. She facilitates adoption and internalization of TransCelerate solutions in alignment with Merck’s objectives. Finally, she watches for opportunities to match innovative approaches to potential process improvement initiatives 359 or other areas of focus.</p><p><strong>Laurie Halloran, CEO, Halloran Consulting Group, Inc. </strong><br />Laurie Halloran founded Halloran Consulting Group in 1998, originally operating out of an unfinished bathroom. Her time as a pediatric ICU nurse had inspired her to start a company 360 that helps move new therapies through FDA processes to get them into the hands of patients desperately in need. By providing a strategic development team, innovative start-up companies could have access to world-class expertise at a fraction of the 361 cost. Since its humble beginnings, Halloran has grown into a leading consultancy of like-minded experts who are dedicated to improving human health by making life science companies better at what they do. Laurie has been named 2018 Women’s Business 362 Enterprise Star by the Women's Business Enterprise National Council (WBENC) and has won a 2017 Enterprising Women of the Year Award from Enterprising Women Magazine. Halloran Consulting Group was also named an Inc. 5000 Fastest Growing Company for 363 the past five years in a row. In 2015, Laurie was honored by the Boston Business Journal as a Woman of Influence, in 2010 was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice, and in 2009, she was awarded Clinical Researcher 364 of the Year by the New England Chapter of the Associate of Clinical Research Professionals. Laurie lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program. She has previously taught at George Washington 365 University and Harvard University. Laurie earned a Bachelor of Science in Nursing from Russell Sage College and a Master of Science in Management from Lesley University. She is also a Prosci Certified Change Practitioner. 366</p><p><strong>Amy Klawitter, Senior Manager, Clinical management, Otsuka Pharmaceutical Development & Commercialization </strong><br />I have worked in clinical research for 23 years and specifically with the pharmaceutical industry for 14 years within 367 clinical management. I currently assist clinical teams to implement RBM (ICH E6 R2) guidance, technology integration for the Otsuka ePlatform and eSurveillance visual analytics. My passion is clinical research and trying to find new and innovative 368 ways to make it easier for patients, sites and researchers.</p><p><strong>Sheri Kuss, Clinical Quality Lead, Clinical Development Quality, Global Product Development, Pfizer, Inc.</strong><br />No bio available.</p><p><strong>Amy Neubauer, Director, Data Quality Oversight, Alkermes </strong><br />Amy Neubauer serves as Director, Data Quality Oversight at Alkermes, a company developing innovative medicines that address the unmet needs and challenges of people living 369 with debilitating diseases, such as schizophrenia, depression, addiction, multiple sclerosis, and cancer. She has 15 years of experience in clinical research with expertise in data management, project management, and vendor management, and is an experienced 370 auditor of clinical trial systems, technologies, services and software. In her current role, Amy is responsible for the development of a clinical data sciences team to lead risk-based approaches and strategic data quality efforts for the organization 371 through development and interpretation of algorithms, code, reports, and visualizations in support of clinical trial operations activities with a focus on impactful data insights and clinical data review. 372</p><p><strong>Jonathan Rowe, Executive Director & Head, Quality Performance and Risk Management, Pfizer </strong><br /></p><p>Jonathan Rowe has more than 20 years of experience supporting pharmaceutical companies in the development of medical therapies from 373 the clinical, operational and business perspectives. Currently, Jonathan holds the position of Executive Director, Head of Clinical Development Quality Performance and Risk Management at Pfizer, where his responsibilities include monitoring, modeling 374 and predicting the Pfizer GCP Quality Management System, leading the analysis of Pfizer’s Clinical Trial Quality Performance and ensuring clinical trial quality risk management is built into all trials. At Pfizer he has held a number of roles 375 including Clinical Director, with responsibility for the Phase IIIb and IV Lipitor program; Director, Intellectual Property Strategy Management; and Senior Director of Process and Performance. Jonathan spent a number of years in “small pharma” 376 as the Head of Intellectual Property and Portfolio Strategy for Amarin and Dignity Scie
376nces. Jonathan earned his Ph.D. and M.S. at the Albert Einstein College of Medicine and his M.A. from Binghamton University.</p><p><strong>Diane Thornton Chandler RBM/Centralized Monitoring Lead, Medtronic </strong><br />Diane’s background and experience includes 20 plus years in various clinical research positions, always with an eye toward process improvement. For the last 377 4 years, her focus has been on building the Centralized Monitoring strategy at Medtronic. Speaking on the topic of RBM and Centralized Monitoring, her emphasis is around cross-functional collaboration and change management as key drivers for program 378 development success.</p><p class="Session">Marissa Volpe, Vice President, Global Clinical Development Operations</p><p style="background:white;">With support from her colleagues, peer’s, and manager; Marissa has built a high-performing, multi-function operations team at Sarepta Therapeutics focused on delivering high quality studies to advance medicine, particularly in the Rare Disease space. She also recently completed teaching her first master’s course at Boston University focusing on clinical trials as part of the clinical research program. Her background includes work in multiple therapeutic areas, but mainly focusing on Multiple Sclerosis before transitioning to oncology in 2015. Marissa learned early on that the patient is the number one priority and continues to work daily to ensure we design and implement more patient centric clinical trials.</p><p><strong>Andy Lawton, Director & Consultant, Risk Based Approach, Ltd. </strong><br />Andy Lawton has extensive experience in computing, statistics, data management, RDE/RDC, system design, Risk Based Approach in both CSV and clinical trials. He is 379 currently consultant and director of Risk Based Approach Ltd and has worked with a variety of companies and institutions on the implementation of ICH E6 R2, ICH E8, QMS/QbD and Risk Based Monitoring. Previously, Andy held the position of Global Head 380 of Clinical Data Management at Boehringer Ingelheim were he also held positions of increasing responsibility during his 32 years with BI. Andy was a Founding Committee Member of ACDM, Member of TransCelerate RBM work stream and a Member of EFPIA WG 381 on Data Transparency. His most notable publications is the paper with Dr. Alistair Ross on GP Audit - throughout 80's and 90's this was the most quoted paper in the BMJ, and he won “best author of the year 2015 and 2016” from the DIA, 382 for the TransCelerate papers on SDV and Central Monitoring in the TIRS Journal.</p><a id="6"></a><p class="Header">Interactive Roundtable Breakout Discussions </p><p><strong>Mike Wenger, Vice President, Patient Engagement, TrialScope</strong><br />In October 2019, TrialScope acquired Clinical Trial Connect and hired its founder, Michael Wenger, as Vice President of Patient Engagement. A brain tumor patient and software 383 developer, Mike is passionate about patient access to clinical trials. Previously, Mike worked at the Michael J. Fox Foundation where he helped develop the Fox Trial Finder, a clinical trial matching platform for Parkinson's disease patients. He also 384 served as an adjunct professor at Rutgers University, teaching a full-stack curriculum. "</p><a id="7"></a><p class="Header">Plenary</p><p><strong>Rob Long, Executive Director, Uplifting Athletes</strong><br />A suburban Philadelphia native, Rob is a former All-American punter at Syracuse and has lived the rare disease journey. In December of 2010, late in his senior season, Rob was diagnosed 385 with anaplastic astrocytoma, a rare and aggressive form of brain cancer. His prognosis at the time was less than encouraging, and his surgery, recovery and treatment took 16 months. Prior to his diagnosis, Rob was on a path to the NFL as a punter, 386 but that opportunity was lost by the time he was healthy enough to train again. A graduate of Syracuse University, Rob pursued a Masters in New Media Management from the S.I. Newhouse School of Public Communications. He also received a B.S. from the 387 Martin J. Whitman School of Management. Rob played football all four years for the Orange and was voted by his teammates as a team captain his final two seasons. He became the second Executive Director of Uplifting Athletes at the end of 2018. Prior 388 to taking over as the Executive Director, Rob served as Uplifting Athletes' Director of Rare Disease Engagement for nearly two years. Rob has a steadfast commitment and connection to the Rare Disease Community as a rare brain cancer patient. As a 389 former star college football student-athlete, his passion and drive to advance the mission of Uplifting Athletes is inspirational. Rob and his wife, Irie, reside in South Philadelphia.</p><p><strong>Charles Makin, Global Head, Real World Evidence Strategy, Biogen </strong><br />Charles Makin leads Biogen’s Real World Evidence Strategy team, overseeing RWE projects across all therapeutic areas for marketed and pipeline products. Before 390 joining Biogen, Mr. Makin served as the General manager/VP for ICON’s RWE-Late Phase Research unit, the world’s second-largest research group dedicated to prospective data collection; and led the team – comprised of several hundred 391 biostatisticians, medical affairs personnel, project/program managers and data management professionals based in >40 countries – to the 2018 Late-Phase CRO Leadership Award. Prior to that, he held leadership positions in major drug commercialization 392 research companies such as IMS, Mapi and Optum, including the roles of VP/Americas Head, Real-World Strategy and Analytics, Head of Observational Outcomes Research (Americas) and Global Head of Research Design and Proposal Development. He has also 393 worked on the payer side (Anthem and Humana), where he led RWE initiatives, economic evaluations and health outcomes research studies. In nearly two decades in RWE, HEOR and drug commercialization, Mr. Makin has developed and implemented drug value, 394 safety and effectiveness roadmaps for most of the top 20 pharmaceutical companies to influence payers, clinicians and HTA bodies and positively impact market access. He has served as Principal Investigator on over a 100 retrospective database analyses 395 (EMR, linked, claims), global registries, medical chart reviews, economic models, PRO studies, physician surveys, ITC/NMAs, SLRs and GVDs across every major therapeutic area. He has also developed >25 value development plans and product market 396 profiles and published on health policy. He has authored over 70 peer-reviewed manuscripts and scientific presentations, serves on the editorial board for multiple journals, and is an invited speaker at several conferences in the US and EU. Mr. Makin 397 holds a BS in Pharmacy from the University of Pune, an MS in Pharmacy Administration (major in outcomes research) from Purdue University, as well as an MBA (Marketing), summa cum laude, and a Master of Management, summa cum laude, both from Goldey-Beacom 398 College. He has also completed a Pharmacoeconomics and Outcomes research Fellowship from Humana.</p><p><strong>Rangaprasad Sarangarajan, PhD, Chief Scientific Officer & SVP, Clinical and Translational Sciences, Research & Development, BERG</strong> <strong></strong><br />
398Rangaprasad (Ranga) Sarangarajan, PhD, is the Senior Vice President and 399 Chief Scientific Officer at BERG who oversees all Research and Development activities including pharmaceutical development & translational sciences strategy development and planning. Dr. Sarangarajan is the co-inventor and co-architect of the 400 BERG Interrogative Biology® technology. This ground-breaking technology is currently focused on next generation R&D innovation in the integration of artificial intelligence-based analytics, bioinformatics and Real-World Data (RWD), and Real-World 401 Evidence (RWE) for speeding up identification/validation of targets, tractability, drug discovery and pharmaceutical development. He is also actively involved in the development of clinical programs in the late stage progress towards registration. 402 Dr. Sarangarajan has numerous U.S. and international patents (granted and pending), covering areas of the discovery platform, cancer, neurology, metabolic diseases, diabetes, obesity and diagnostics. He has published extensively and has presented 403 his research at national and international medical and scientific meetings. He co-authored and co-edited Cellular Respiration and Carcinogenesis, a first of its kind treatise on the role of mitochondrial function and metabolic network regulation in 404 the etiology of cancer as it pertains to the seminal observations made by Otto Warburg.</p><p><strong>Maura Snyder, MBA, Director, Patient Engagement Strategy & Portfolio, Janssen</strong><br />Maura is the Director, Patient Engagement Strategy & Portfolio within the Investigator & Patient Engagement organization at Janssen. In this 405 role, Maura oversees the IPE Portfolio team, Janssen's dedicated trial recruitment and retention experts, responsible for turning insight into action to design and implement impactful solutions that will enhance the clinical trial experience for the 406 patient, their caregivers and clinical research sites. Prior to joining the Investigator & Patient engagement team, Maura served as Strategic Lead for Value Excellence team within Janssen’s commercial organization, launching a strategic 407 marketing framework based on delivering customized value to stakeholders, based on stakeholders’ needs. Maura has held various positions within the clinical and commercial sides of the business. Through these roles, she has contributed to key 408 decisions across the all product stages, pre-clinical through in-line. Maura holds a Bachelor of Arts degree from Villanova University and her Masters of Business Administration from Seton Hall University.</p><p><strong>Alik Farber, MD, Chief, Division of Vascular and Endovascular Surgery, Associate Chair for Clinical Operations, Department of Surgery, Boston Medical Center</strong> <br />Alik Farber, MD is Chief of the Division of Vascular and Endovascular 409 Surgery at Boston Medical Center and Professor of Surgery and Radiology at Boston University School of Medicine. Dr. Farber is a graduate of Brown University and obtained his medical degree from Harvard Medical School. He completed a residency in 410 general surgery at Massachusetts General Hospital, a vascular surgery fellowship at Dartmouth-Hitchcock Medical Center and an endovascular surgery fellowship at the Southern Illinois School of Medicine. Dr. Farber’s administrative responsibilities 411 include being Associate Chair for Clinical Operations in the Department of Surgery, Chair of Value Analysis Committee and Co-Director of Non-Invasive Vascular Laboratories. Dr. Farber is currently a National Co-Chair of the Best Endovascular versus 412 Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial, a randomized, controlled trial enrolling patients at 135 sites across North America, Europe and New Zealand. BEST-CLI is funded by a $25 million grant awarded by the National 413 Institutes of Health.</p><p><strong>Peter Bergethon, MD, Vice President, Head of Digital and Quantitative Medicine, Biogen</strong> <br />Peter R. Bergethon, MD is Vice President and Head of Quantitative Medicine and Clinical Technologies (QMCT) at Biogen. He leads the identification 414 of technologies and methodologies that transform drug development. QMCT creates value b
414y leading the transition of clinical practice in Biogen’s core and emerging growth areas from a qualitative to a quantitative discipline, and connecting the 415 Clinical with the Research enterprise, to advance therapeutics and personalized medicine. Peter came to Biogen in 2017 from Pfizer Worldwide Research and Development where he was Vice President and Head of the Pfizer Innovation Research Lab within 416 the Early Clinical Development group. At Pfizer, Peter led both the Quantitative Medicine group and the Innovation Research Labs where he pioneered mobile and digital clinical assessment technology, human neurophenotyping, and multi-modal data analytics 417 to accelerate clinical development in neuroscience, immunology, rare diseases, and cardiometabolic disease. He is an accomplished clinical neurologist and neuroscientist who, prior to joining Pfizer, was a Professor at Boston University and Tufts 418 University in the Departments of Biochemistry, Neurology, Neurobiology & Anatomy, and Biomedical Engineering.</p><p><strong>Alan Louie, PhD, Research Director, Life Sciences, IDC Health Insights</strong> <br />Dr. Louie leads IDC Health Insights' Life Science R&D Strategy and Technology Research with a focus on ongoing innovation and best practices in life science 419 R&D. He brings more than 35 years of technology, product and strategy development from across the life science industry. In his time at IDC, Dr. Louie has authored more than 250 reports on innovation in the life sciences. Over his career, he was 420 responsible for the development and commercialization of more than 30 products for a variety of industries, including many first-in-class product offerings. Dr. Louie has a PhD in Biochemistry from the University of California at Riverside. 421</p></div> 422</div></div> 423 </div> 424 <div class="col-sm-3"> 425 <div id="Contentplaceholder1_TEE75556F001_Col01" class="sf_colsIn pad-lr" data-sf-element="Column 2" data-placeholder-label="Column 2"><div class='sfContentBlock'><!-- Social Icons --> 426<br class="hidden-md hidden-lg" /> 427<div class="social-icons"> 428<a href="http://gate250.com/outlook/20/CTL20.ics" target="_blank" title="Outlook"><img alt="Outlook" class="social-icon" src="/images/default-source/social/calendar-gray.png" title="Outlook" /></a> <a href="http://www.youtube.com/CambridgeHealthtech/" target="_blank" title="YouTube"><img alt="YouTube" class="social-icon" src="/images/default-source/social/youtube-gray.png" title="YouTube" /></a> <a href="https://www.facebook.com/HealthtechConferences/" target="_blank" title="Facebook"><img alt="Facebook" class="social-icon" src="/images/default-source/social/facebook-gray.png" title="Facebook" /></a> <a href="http://www.linkedin.com/groups?gid=3711305&trk=myg_ugrp_ovr" target="_blank" title="LinkedIn"><img alt="LinkedIn" class="social-icon" src="/images/default-source/social/linkedin-gray.png" title="LinkedIn" /></a> <a href="http://twitter.com/CHI_Healthtech" target="_blank" title="Twitter"><img alt="Twitter" class="social-icon" src="/images/default-source/social/twitter-gray.png" title="Twitter" /></a> 429</div> 430<!-- Translation --> 431<div class="sidebar-hashtag"> 432<strong>#CLIN20</strong> 433</div> 434<hr /> 435<div class="text-center"> 436<a href="https://www.giievent.jp/chi917785/" target="_blank" title="Japanese"><img alt="Japan-Flag" src="/images/default-source/default-album/Japan.png" title="Japan-Flag" /></a> 437<a href="https://www.giievent.kr/chi917785/" target="_blank" title="Korean"><img alt="Korea-Flag" src="/images/default-source/default-album/Korea_t.png" title="Korea-Flag" /></a> 438<a href="http://cn.giievent.tw/chi917785/" target="_blank" title="Chinese - Simplified"><img alt="China-Simplified-Flag" src="/images/default-source/default-album/China-Simplified_t.png" title="China-Simplified-Flag" /></a> 439<a href="http://www.giievent.tw/chi917785/" target="_blank" title="Chinese - Traditional"><img alt="China-Traditional-Flag" src="/images/default-source/default-album/China-Traditional_t.png" title="China-Traditional-Flag" /></a> 440</div> 441<hr /> 442<div> 443 </div> 444<div class="sidebar-item"> 445<a href="/sponsorship-opportunities"><img alt="Sponsor Exhibit" src="/images/librariesprovider49/sidebar/20/Sponsor-Exhibit.png" class="imageResize" /></a> 446</div> 447<div class="sidebar-item"> 448<a href="/docs/librariesprovider49/brochures/ctl-2020-cag.pdf" target="_blank"><img alt="" src="/images/librariesprovider49/sidebar/20/cag.png" class="imageResize" /></a> 449</div> 450<div class="sidebar-item"> 451<a href="/attendees"><img alt="Attendee List" src="/images/librariesprovider49/sidebar/20/attendeelist.png" class="imageResize" /></a> 452</div> 453<div class="sidebar-item"> 454<a href="/media-partners"><img alt="Media Partners" src="/images/librariesprovider49/sidebar/20/media-partners.png" class="imageResize" /></a> 455</div> 456<br /> 457<div class="sidebar-item sidebar-block"> 458<p class="light-blue quaternary-text"><strong>Partnering & Sponsorship</strong></p> 459<p><span class="grey"><strong>Companies A-K</strong></span><br /> 460<span class="grey"><strong>Ilana Quigley</strong></span><br /> 461<em>Sr. Manager, Business Development</em><br /> 462<em>Cambridge Healthtech Institute (CHI)</em><br /> 463+1 781.972.5457<br /> 464<a href="mailto:[email protected]">[email protected]</a></p> 465<p><span class="grey"><strong>Companies L-Z</strong></span><br /> 466<span class="grey"><strong>Patty Rose</strong></span><br /> 467<em>Sr. Manager, Business Development</em><br /> 468<em>
468Cambridge Healthtech Institute</em><br /> 469+1 781.247.1349<br /> 470<a href="mailto:[email protected]">[email protected]</a></p> 471<p class="light-blue quaternary-text"><strong>Group Discounts</strong></p> 472<p><span class="grey"><strong>Melissa Dolen</strong></span><br /> 473<em>Sr. Account Manager</em><br /> 474<em>Cambridge Healthtech Institute</em><br /> 475+1 781.972.5418<br /> 476<a href="mailto:[email protected]">[email protected]</a></p> 477<p class="light-blue quaternary-text"><strong>Media Partnerships</strong></p> 478<p><span class="grey"><strong>James Prudhomme<br /> 479</strong></span><em>Sr. Marketing Manager</em><br /> 480<em>Cambridge Healthtech Institute</em><br /> 481(+1) 781.972.5486<br /> 482<a href="mailto:[email protected]">[email protected]</a></p> 483</div> 484<p class="light-blue quaternary-text text-center pad-top"><strong>From the Producers of:</strong></p> 485<img alt="From the Producers of SCOPE" src="/images/librariesprovider49/sidebar/20/scope.png" class="imageResize" /> 486<div class="sidebar-item"> 487<a href="http://www.scopesummit.com/webinars"><img src="/images/librariesprovider49/sidebar/20/scope-right-column-webinars.png" class="imageResize" alt="SCOPE" /></a></div> 488 489</div></div> 490 </div> 491</div> 492 </div> </div> </div> <footer> 493 494<div > 495 <div class="sf-Long-text" ><div class="footer"><div class="container"><div class="row"><div class="col-sm-3 col-xs-12"><div class="footer-small"><div class="footer-small-inner"><img alt="CHI | Cambridge HealthTech Institute" class="CII-footer" src="/UploadedImages/CHI-logo.png" data-sf-ec-immutable="" /><br /><p>250 First Avenue, Suite 300<br />Needham, MA 02494<br /><br />P: 781.972.5400<br />F: 781.972.5425 496 <br />E: <a href="mailto:[email protected]?cdtConferenceId=404272006.1663694140&cdtRollupId=404272006.1663694140" data-sf-ec-immutable="">[email protected]</a> 497 </p><div class="row"><div class="col-sm-12 footer-social"><a href="https://twitter.com/CHI_Healthtech" data-sf-ec-immutable=""><img class="footer-social-icons" src="/images/default-source/social/twitter-gray.png?sfvrsn=bac909e7_7" alt="Twitter Icon" /></a> 498 499 <a href="https://www.linkedin.com/company/cambridge-healthtech-institute"><img class="footer-social-icons" src="/images/default-source/social/linkedin-gray.png?sfvrsn=ed70471e_4" alt="LinkedIn Icon" /></a> 500 501 <a href="https://www.facebook.com/HealthtechConferences" data-sf-ec-immutable=""><img class="footer-social-icons" src="/images/default-source/social/facebook-gray.png?sfvrsn=35d4a48c_4" alt="Facebook Icon" /></a> 502 </div></div></div></div></div><div class="col-sm-4 footer-border hidden-xs"><div class="row"><div class="col-sm-12"><p>Life Science Portals</p></div><div class="col-sm-6"><p><a href="http://biologicaltherapeutics.cambridgeinnovationinstitute.com/home">Biological Therapeutic Products</a></p><p><a href="http://biomarkers.cambridgeinnovationinstitute.com/home">Biomarkers & Diagnostics</a></p><p><a href="http://biopharmastrategy.cambridgeinnovationinstitute.com/home">Biopharma Strategy</a></p><p><a href="https://bioprocessing.cambridgeinnovationinstitute.com/home">Bioprocess & Manufacturing</a></p><p><a href="http://chemistry.cambridgeinnovationinstitute.com/home">Chemistry</a></p><p><a href="http://clinicaltrials.cambridgeinnovationinstitute.com/home">Clinical Trials &<br data-sf-ec-immutable="" />Translational Medicine</a></p><p><a href="http://druganddevice.cambridgeinnovationinstitute.com/home">Drug & Device Safety</a></p></div><div class="col-sm-6"><p><a href="http://drugdevelopment.cambridgeinnovationinstitute.com/home">Drug Discovery & Development</a></p><p><a href="http://drugtargets.cambridgeinnovationinstitute.com/home">Drug Targets</a></p><p><a href="http://healthcare.cambridgeinnovationinstitute.com/home">Healthcare</a></p><p><a href="http://it.cambridgeinnovationinstitute.com/home">IT, AI, ML & Informatics</a></p><p><a href="http://techtools.cambridgeinnovationinstitute.com/home">Technology & Tools For<br data-sf-ec-immutable="" />Life Science</a></p><p><a href="http://therapeutics.cambridgeinnovationinstitute.com/home">Therapeutic Indications</a></p><p><a href="https://www.cambridgeinnovationinstitute.com/vip-series" data-sf-ec-immutable="">Venture, Innovation & Partnering</a></p></div></div></div><div class="col-sm-3 footer-border hidden-xs"><p>CHI Divisions</p><p><a href="https://www.healthtech.com/?cdtConferenceId=404272006.1663694140&cdtRollupId=404272006.1663694140" data-sf-ec-immutable="">Conferences</a></p><p><a href="https://www.insightpharmareports.com/" data-sf-ec-immutable="">Reports & Market Research</a></p><p><a href="https://www.healthtech.com/publishing" data-sf-ec-immutable="">News & Advertising</a></p><p><a href="https://proservices.healthtech.com/?cdtConferenceId=404272006.1663694140&cdtRollupId=404272006.1663694140" data-sf-ec-immutable="">Professional Services</a></p></div><div class="col-sm-2 footer-border hidden-xs"><p>Corporate Information</p><p><a href="https://www.cambridgeinnovationinstitute.com/" data-sf-ec-immutable="">Cambridge Innovation<br />
502Institute</a></p><p><a href="https://www.cambridgeinnovationinstitute.com/Executive-Team/" data-sf-ec-immutable="">Executive Team</a></p><p><a href="https://www.cambridgeinnovationinstitute.com/Testimonials/" data-sf-ec-immutable="">Testimonials</a></p><p><a href="https://www.cambridgeinnovationinstitute.com/mailing-list.html" data-sf-ec-immutable="">Mailing List</a></p><p><a href="https://www.cambridgeinnovationinstitute.com/Careers/" title="Careers" data-sf-ec-immutable="">Careers</a></p><hr /><p><a href="https://www.cambridgeinnovationinstitute.com/request-information" data-sf-ec-immutable="">Request Information</a></p><p><a href="https://www.cambridgeinnovationinstitute.com/Privacy-Policy/" data-sf-ec-immutable="">Privacy Policy</a></p></div></div></div></div></div> 503</div> </footer> 504
505<script type="text/javascript"> 506//<![CDATA[ 507window.__TsmHiddenField = $get('ctl04_TSM');;(function() { 508 function loadHandler() { 509 var hf = $get('ctl05_TSSM'); 510 if (!hf._RSSM_init) { hf._RSSM_init = true; hf.value = ''; } 511 hf.value += ';Telerik.Sitefinity.Resources, Version=15.3.8525.0, Culture=neutral, PublicKeyToken=b28c218413bdf563:en:b494eb86-d40a-44e5-a7dc-aca57f5f48a3:7a90d6a'; 512 Sys.Application.remove_load(loadHandler); 513 }; 514 Sys.Application.add_load(loadHandler); 515 })();//]]> 516</script>
516 517</form>
517<script type="application/json" id="PersonalizationTracker"> 518 {"IsPagePersonalizationTarget":false,"IsUrlPersonalizationTarget":false,"PageId":"484edf1e-fd00-4e2e-b491-15fcb4b779a8"} 519</script>
519<script type="text/javascript" src="/WebResource.axd?d=NjxTqR2bqTw1rewxxlkHPmgAfJuIZatZQsgiv9VXeuS4b3jDSP0iC08qtnhjAyLt8rNV7Q_-P2b5NeKZmFfuIqAo8swrWY7MdHcIQq5QplyOsxLsCkzNuAEB4CAJle8tPj0rBzWbC4IscCx9QWlKOg00HY0dtg58E6YLTvIm3Pey6uh4ZGIzLfqdujM66zmobwGj7EdEi08vS-nFvw1HBDi0des5lBOjuzOTijePpiE1&t=638923854120000000"> 520 521</script>
521<script type="text/javascript" src="/bower_components/js-url/url.min.js"></script>
521<script type="text/javascript" src="/js/TrackClicks.js"></script>
521<script type="text/javascript" src="/js/CrossDomainClient.js"></script>
521</body> </html>
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.